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ABSTRACT
Objectives Juvenile idiopathic arthritis ( JIA) is a
heterogeneous group of diseases, comprising seven
categories. Genetic data could potentially be used to
help redeﬁne JIA categories and improve the current
classiﬁcation system. The human leucocyte antigen (HLA)
region is strongly associated with JIA. Fine-mapping of
the region was performed to look for similarities and
differences in HLA associations between the JIA
categories and deﬁne correspondences with adult
inﬂammatory arthritides.
Methods Dense genotype data from the HLA region,
from the Immunochip array for 5043 JIA cases and
14 390 controls, were used to impute single-nucleotide
polymorphisms, HLA classical alleles and amino acids.
Bivariate analysis was performed to investigate genetic
correlation between the JIA categories. Conditional
analysis was used to identify additional effects within
the region. Comparison of the ﬁndings with those in
adult inﬂammatory arthritic diseases was performed.
Results We identiﬁed category-speciﬁc associations and
have demonstrated for the ﬁrst time that rheumatoid
factor (RF)-negative polyarticular JIA and oligoarticular
JIA are genetically similar in their HLA associations. We
also observe that each JIA category potentially has an
adult counterpart. The RF-positive polyarthritis
association at HLA-DRB1 amino acid at position 13
mirrors the association in adult seropositive rheumatoid
arthritis (RA). Interestingly, the combined oligoarthritis
and RF-negative polyarthritis dataset shares the same
association with adult seronegative RA.
Conclusions The ﬁndings suggest the value of using
genetic data in helping to classify the categories of this
heterogeneous disease. Mapping JIA categories to adult
counterparts could enable shared knowledge of disease
pathogenesis and aetiology and facilitate transition from
paediatric to adult services.

INTRODUCTION
Juvenile idiopathic arthritis ( JIA), the most common
arthritic disease of childhood, is a heterogeneous

group of diseases. The current International League
of Associations for Rheumatology (ILAR) classiﬁcation system deﬁnes seven categories based on clinical
features, including an undifferentiated category for
cases that do not fall into one of the deﬁned categories.1 Genetic data could be used to help deﬁne JIA
categories and improve the current classiﬁcation
system. Prior studies of the best established genetic
risk factor for JIA, the major histocompatibility
region (MHC) on chromosome 6, have been in
modest sample sizes.2 3 The development of methods
for imputation of classical human leucocyte antigen
(HLA) alleles and amino acids4 from genotyping
array data enables a comprehensive and cost-effective
approach for generating HLA typing on much larger
JIA cohorts. We sought to use this powerful approach
to dissect and reﬁne the HLA associations of the heterogeneous JIA categories.
While there are considerable clinical similarities
between some JIA categories and adult inﬂammatory arthritides, there is also substantial heterogeneity. Hence, we sought to compare the associations
across the MHC region observed in JIA cohorts
with those observed in adult inﬂammatory arthritides, such as rheumatoid arthritis (RA).5 6
Furthermore, some categories of JIA have obvious
adult counterparts (eg, enthesitis-related arthritis
(ERA) and adult ankylosing spondylitis (AS), or
juvenile psoriatic arthritis ( jPsA) with psoriatic
arthritis), the most common categories of JIA, oligoarthritis and rheumatoid factor (RF)-negative
polyarthritis, do not appear to map to any adult
form of disease. Mapping each of the JIA categories
to RA and other adult inﬂammatory arthritic diseases could have many beneﬁts including enhanced
understanding of the genetic basis and etiopathogenesis of inﬂammatory arthritis in general, allow
extrapolation of results from clinical trials in adult
inﬂammatory arthritis to paediatric counterparts to
improve the therapy of JIA, and facilitate smooth
transition of paediatric patients to adult care providers with consistent clinical designations.
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The goals of this study were threefold, to use comprehensive
MHC ﬁne-mapping genetic data to reﬁne HLA associations
across each JIA category, to assess correspondences between the
JIA categories and ﬁnally compare associations with adult
inﬂammatory arthritic diseases.

METHODS
Subjects
All cohorts comprised individuals from populations of
European descent from the USA, UK, Canada, Norway and
Germany. Descriptions of the datasets can be found in the
online supplementary information. The total dataset prequality
control comprised all JIA categories and included 5737 patients
with JIA and 16 403 controls genotyped for 191 494 markers.

Genotyping and quality controls
Samples were genotyped using ImmunoChip, a custom-made
Illumina Inﬁnium array, described previously.7 The
ImmunoChip includes dense coverage of the HLA region and
186 additional non-HLA loci. Genotyping was performed
according to Illumina’s protocols at labs in Hinxton, UK,
Manchester, UK, Cincinnati, USA, Utah, USA, Charlottesville,
USA, New York, USA, Brisbane, Australia and Toronto, Canada.
The Illumina GenomeStudio GenTrain V.2.0 algorithm was used
to recluster all 22 140 samples together.
Single-nucleotide polymorphisms (SNPs) were initially
excluded if they had a call rate <98% and a cluster separation
score of <0.4. A SNP was subsequently removed from the
primary analysis, if it exhibited signiﬁcant differential missingness between cases and controls ( p<0.05), had signiﬁcant
departure from Hardy-Weinberg equilibrium ( p<0.000001 in
cases or p<0.01 in controls), or had a minor allele frequency
(MAF) <0.01. Based on the SNPs that passed the above quality
control thresholds, samples were then excluded for call rate
<98%, or if there were inconsistencies between recorded and
genotype-inferred gender or excess heterozygosity on the autosomes. Duplicates and ﬁrst-degree or second-degree relatives
were removed based on identity-by-descent statistics computed
using the programme KING.8 Admixture estimates were computed on the remaining samples while including the HapMap
phase III individuals (CEU, YRI and CHB) as reference populations using the software ADMIXTURE.9 The admixture estimates were then used to identify and remove genetic outliers.
Three of these admixture estimates were included as covariates
in the logistic regression (association) analysis to account for
within-sample variation.

HLA imputation
The markers spanning 29–34 Mb (hg build19) on chromosome
6 which encompasses the HLA region were extracted from the
post-QC Immunochip dataset. Cases and controls were imputed
together using SNP2HLA (V.1.0) (http://www.broadinstitute.org/
mpg/snp2hla/).4 This is a robust approach which enables imputation of classical HLA alleles as well as speciﬁc amino acid positions within HLA alleles, which may play an important
functional role. The method uses a large reference dataset collected by the type 1 diabetes genetics consortium10 (n=5225).
This dataset has gold-standard HLA typing and high SNP
density, thus using linkage disequilibrium patterns around SNPs
and classical HLA alleles enables the inference of classical HLA
alleles, amino acids and SNPs across the region based on the
SNP data generated from Immunochip, an approach successfully
used by a number of researchers.5 6 11 12 Post-imputation QC
included removing variants with a MAF <0.01 and variants
766

with an r2 <0.8. The dosage output, which accounts for imputation uncertainty, was used for the association analyses.
To assess the quality of the imputation, a proportion of the
UK and the US JIA cases have two-digit and four-digit
HLA-DRB1 typing available (n=1562) performed using a semiautomated, reverse dot-blot method,2 3 which was used to
calculate the proportion of accurately imputed two-digit and
four-digit HLA-DRB1 alleles. In addition, the DRB1 two-digit
and four-digit allele frequencies were compared between genotyped and imputed HLA allele calls.

Association analysis of HLA alleles and amino acid
polymorphisms
To compare the differences and similarities of HLA associations
across the different JIA categories, genetic correlation of the
MHC region between the categories was calculated using bivariate analysis13 implemented using GCTA.14 This analysis ﬁrst calculates the genetic variance (heritability) of each category and
then calculates the genetic correlation between the categories
across the HLA region. High correlation suggests similarities or
pleiotropy between the two categories compared. This analysis
requires independent controls for the two categories being compared and therefore the controls were randomly assigned to the
two categories, splitting equally, taking into account the proportions of controls from each population.
HLA variants were binary coded (presence or absence) and
included SNPs and two-digit and four-digit HLA alleles.
Association analysis was performed using logistic regression in
R, using dosage data (genotype probabilities), which takes into
account imputation uncertainty. For the analysis of each JIA category, the total control dataset was used for each comparison.
HLA amino acid polymorphisms have multiple residues at each
position and were analysed using the omnibus test. This is a
log-likelihood ratio test comparing the likelihood of the null
model against the likelihood of the ﬁtted model, which gave a p
value assessing the improvement in ﬁt of the model, the deviance is calculated (−2×the log likelihood ratio), which follows a
χ2 distribution with m−1 degrees of freedom (where m is the
number of HLA variant alleles).5 Three of the admixture estimates were included as covariates to account for potential population stratiﬁcation.
To look for independent effects across the HLA region, conditional analysis was performed. Logistic regression, as described
above, was performed to identify the most associated marker.
Then this marker was used as a covariate in the model and logistic regression repeated. This analysis was continued sequentially
in a forward stepwise approach until no variant satisﬁed the
genome-wide signiﬁcance threshold (conditioned p<5×10−8).
When the covariate was an amino acid, all multi-allelic variants
of the amino acid were included as covariates, excluding the
most frequent variant. To look for additional effects outside
HLA-DRB1, we included all two-digit and four-digit HLA-DRB1
alleles within the model and looked for any residual effects.
To conﬁrm the results of the conditional analysis and to
check that there were no other combinations of variants that
better ﬁtted the models derived from the forward stepwise
approach, described above, we exhaustively tested all possible
combinations of 2, 3 and 4 amino acid positions, including the
three admixture estimates as covariates. For each combination
we calculated deviation from the null hypothesis, which
included only the admixture covariates. To assess the improvement in the model ﬁt we also calculated the improvement in the
Akaike information criterion (ΔAIC), and also the improvement
in the Bayesian information criterion (ΔBIC).
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We used a disease prevalence of 0.001 to estimate the variance explained (h2) by the HLA region and some of the independent effects and compared with the estimate calculated for
all Immunochip, implemented using GCTA.14

RESULTS
HLA imputation
Post-QC data was available for 6920 SNPs, 335 amino acids and
171 HLA alleles in 5043 JIA cases and 14 390 healthy controls
(see online supplementary table S1). A detailed breakdown of
the JIA cases by ILAR category is shown in table 1, and by
population and gender in online supplementary table S2.
For a proportion of the UK and US JIA cases (n=1562), twodigit and four-digit HLA-DRB1 classical typing was available.
The accuracy of the imputed data was calculated as 97.9% for
two-digit and 89.3% for four-digit alleles, which is similar to
those calculated in previous studies in RA.5 A detailed analysis
strategy is shown in online supplementary ﬁgure S1.

Bivariate analysis to look for genetic correlation between
the JIA categories
We performed bivariate analysis to calculate the estimated HLA
region genetic correlation between each pair of JIA categories
(ﬁgure 1). The heritability for each category estimated from the
bivariate analysis was similar to that estimated from univariate
analyses performed in the total dataset (see online
supplementary tables S3 and S4). The estimates of correlation
between each pair of JIA categories showed a surprisingly strong
correlation between the most common categories of JIA:
RF-negative polyarthritis, persistent and extended oligoarthritis
(rG>0.88). In contrast, the correlations between these three categories and the other categories of JIA were lower (ﬁgure 1).

supplementary table S5 and supplementary ﬁgure S2). When
the effect estimates for the histidine13 residue in the associated
JIA categories were compared using multinomial logistic regression, strong protective effects were observed in persistent and
extended oligoarthritis, with no signiﬁcant difference in the
effect estimates ( p=0.63). There was a slightly weaker, protective effect for RF-negative polyarthritis compared with that for
persistent and extended oligoarthritis (p<0.05). Importantly,
there was a signiﬁcantly different risk effect in RF-positive polyarthritis compared with RF-negative polyarthritis, persistent and
extended oligoarthritis. The remaining JIA categories had distinct HLA associations from these common categories. The
most signiﬁcant association in systemic JIA (sJIA) was for
HLA-DRB1*11 and for the ERA category was HLA-B*27. For
jPsA, no associations reached genome-wide level of signiﬁcance
(p<5×10−8).

Investigation of multiple effects within the region
Observing that oligoarthritis and RF-negative polyarthritis
showed similar HLA associations and evidence for pleiotropy
from the bivariate analysis in GCTA,13 14 these categories were
combined to increase power for further analyses (total sample
size=3934). To look for independent genetic effects across the
HLA region, we conditioned on the most associated marker,
HLA-DRB1 amino acid 13 and detected a second independent
effect within HLA-DRB1 at amino acid position 67 (omnibus
p=7.01×10−83). Further conditioning revealed separate effects
at amino acid positions 181 (omnibus p=3.33×10−22) and 71

Association analysis of HLA markers
After conducting primary association analysis of all 7426 variants, in each of the seven JIA categories (table 2), we observed
that for oligoarthritis and both RF-positive and RF-negative
polyarthritis the strongest association was with HLA-DRB1
amino acid position 13. However, for oligoarthritis and
RF-negative polyarthritis, the most common categories of JIA,
glycine13 confers the strongest risk; serine13 also confers a risk
effect but histidine13 is protective. By contrast, in RF-positive
polyarthritis, it is histidine13 that confers the strongest risk and
serine13 confers a strong protective effect (see ﬁgure 2, online

Table 1 Breakdown of the total JIA cohort by ILAR category
ILAR category

Number

All JIA

5043

Systemic JIA

373

Oligoarthritis
Persistent

1751

Extended

658

RF-negative polyarthritis

1525

RF-positive polyarthritis

337

Enthesitis-related arthritis

183

Juvenile psoriatic arthritis

112

Undifferentiated

104

Combined oligoarthritis and RF-negative polyarthritis dataset

3934

ILAR, International League of Associations for Rheumatology; JIA, juvenile idiopathic
arthritis; RF, rheumatoid factor.

Figure 1 Heatmap showing genetic correlation for human leucocyte
antigen (HLA) between the juvenile idiopathic arthritis ( JIA) categories.
Each square shows the level of correlation between each JIA category.
With a scale of red colour representing higher correlation through
orange to yellow for low correlation. The numbers within the squares
represent the correlation values ranging from 0 to 1 for high
correlation. Note that this plot is symmetrical. POligo, persistent
oligoarthritis; EOligo, extended oligoarthritis; RF, rheumatoid factor;
RFnegpoly, RF-negative polyarthritis; RFpospoly, RF-positive
polyarthritis; sJIA, systemic JIA; ERA, enthesitis-related arthritis; jPsA,
juvenile psoriatic arthritis.
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Table 2

Primary association of the HLA region in JIA ILAR categories

Category

HLA variant primary association

Position

p Value

Amino acid residue

OR

−11

95% CI

Systemic JIA

HLA-DRB1*11

32660042

2.09

1.67 to 2.59

Persistent oligoarthritis

HLA-DRB1 AA pos 13

32660109

9×10−256

Glycine

2.72

2.41 to 3.08

Extended oligoarthritis

HLA-DRB1 AA pos 13

32660109

1.05×10−104

Glycine

2.87

2.4 to 3.42

RF-negative polyarthritis

HLA-DRB1 AA pos 13

32660109

4.29×10−99

Glycine

2.02

1.76 to 2.32

RF-positive polyarthritis

HLA-DRB1 AA pos 13

32660109

3.65×10−31

Histidine

2.44

2.0 to 2.97

ERA

HLA-B*27

31431272

8.81×10−98

1.71

1.32 to 2.24

3.41×10

ERA, enthesitis-related arthritis; HLA, human leucocyte antigen; ILAR, International League of Associations for Rheumatology; JIA, Juvenile idiopathic arthritis; RF, rheumatoid factor.

(omnibus p=1.16×10−8) (see online supplementary table S6
and supplementary ﬁgure S3). Conditioning on all two-digit and
four-digit HLA-DRB1 alleles found independent effects at
HLA-DPB1*02:01, HLA-A amino acid 95 and HLA-B amino
acid 152 (see online supplementary table S6 and ﬁgure 3). All
possible combinations of 2, 3 and 4 amino acids in HLA-DRB1
were exhaustively tested. HLA-DRB1 amino acids 13 and 67
were the most strongly associated of all possible 2 amino acid
combinations. However, for both the 3- amino acid and
4-amino acid combinations, there were two other combinations
that had a better model, according to deviance from the null
hypothesis, compared with the combination of HLA-DRB1
amino acids at positions 13, 67 and 181 or for HLA-DRB1 at
positions 13, 67, 181 and 71, the 3- and 4-amino acid models
that might have been expected to be the most signiﬁcant considering the results of the conditional analysis. Therefore, while
there appears to be multiple independent effects within the
HLA-DRB1 gene, we can only be conﬁdent in the HLA-DRB1
amino acids at positions 13 and 67.

Variance explained by the HLA region
We calculated the proportion of variance explained by the independent HLA variants in the combined oligoarthritis and
RF-negative polyarthritis dataset (see table 3 and online
supplementary table S4) and found that the total HLA region

explained 8% of the total phenotypic variance, with the
HLA-DRB1 region, driven by the amino acid at position 13,
contributing 50% of variance explained by the HLA region.

Comparison with adult inﬂammatory arthritic diseases
We compared our HLA association ﬁndings across JIA categories
with those of adult inﬂammatory arthritic diseases (see online
supplementary table S7). In seropositive RA, Raychaudhuri et al
showed multiple independent associations within the HLA-DRB1
gene at three amino acid positions (11, 71 and 74) and also independent associations at amino acid position 9 in HLA-B and
amino acid position 9 in HLA-DPB1.5 The DRB1 amino acid at
position 11 is in strong linkage disequilibrium with the amino
acid at position 13, which makes it difﬁcult to assign causality to
one or the other. In this study, oligoarthritis and polyarthritis
each showed association with HLA-DRB1 amino acid at position
13. If the ORs of the residues at HLA-DRB1 amino acid position
13 for paediatric and adult arthritic diseases are compared, the
combined oligoarthritis and RF-negative polyarthritis dataset
shows similar ORs to that seen in seronegative RA6 (see online
supplementary ﬁgure S4), suggesting that these JIA categories
could potentially have an adult counterpart. Likewise, in
RF-positive polyarthritis, the histidine residue at position 13 at
HLA-DRB1 confers the greatest risk for disease and, unsurprisingly, this mirrors the association in seropositive RA5 (see online
supplementary ﬁgure S4). For the ERA category, as expected the
most signiﬁcant association was for HLA-B*27, the same HLA
allele found in AS.

DISCUSSION

Figure 2 Different effect sizes (ORs and 95% CIs) for amino acid
residues at human leucocyte antigen (HLA)-DRB1 position 13 between
the combined dataset of oligoarthritis and rheumatoid factor
(RF)-negative polyarthritis compared with those for RF-positive
polyarthritis.
768

This is the largest investigation of association of the HLA region
with JIA and its categories to date, exploiting novel imputation
strategies we have observed differences and similarities between
HLA associations for the different categories. The most
common and also the most clinically homogeneous categories of
JIA, oligoarthritis and RF-negative polyarthritis, showed strong
genetic correlation across the HLA region supporting our previous approaches of combining these categories for genetic
studies.15 Combined analysis of these categories show they share
association across the HLA region with strong association for
HLA-DRB1 amino acid position 13. The results for these combined categories are consistent with previous ﬁndings investigating association of classical HLA alleles in JIA. For example,
there is previous evidence for association of HLA-DRB1*08 and
the HLA alleles that lie on this haplotype, with oligoarthritis
and RF-negative polyarthritis.2 3 At HLA-DRB1 amino acid position 13, the glycine residue lies on the HLA-DRB1*08 haplotype. The association with the amino acids is much stronger
than that for the classical HLA allele (see online supplementary
ﬁgure S3A). These combined categories also show multiple independent effects across the region, at HLA-DRB1 amino acid
Hinks A, et al. Ann Rheum Dis 2017;76:765–772. doi:10.1136/annrheumdis-2016-210025
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Figure 3 Analysis in the combined dataset of persistent and extended oligoarthritis and rheumatoid factor (RF)-negative polyarthritis, evidence for
multiple independent effects across the major histocompatibility region (MHC). (A) Association results for all human leucocyte antigen (HLA)
markers, HLA-DRB1 amino acid position 13 showed the strongest association ( p<10−377). (B) Conditioning on all HLA-DRB1 two-digit and four-digit
alleles, HLA-DPB1*02:01 was associated ( p<10−57). (C) Conditioning on all HLA-DRB1 two-digit and four-digit alleles and HLA-DPB1*02:01, HLA-A
amino acid position 95 was associated ( p<10−37). (D) Conditioning on all HLA-DRB1 two-digit and four-digit alleles, HLA-DPB1*02:01 and HLA-A
amino acid position 95, HLA-B amino acid position 152 was associated ( p<10−10).
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Table 3 Heritability estimates for HLA and various alleles and All
Immunochip in the combined oligoarthritis and RF-negative
polyarthritis dataset (n=3934)
Cohort

h2SNP(SE)

All Immunochip

0.17 (0.006)

Total HLA region

0.08 (0.007)

All Immunochip without HLA

0.09 (0.006)

HLA-DRB1 2D/4D alleles

0.04 (0.008)

HLA-DPB1 2D/4D alleles
HLA-A 2D/4D alleles

0.02 (0.005)
0.006 (0.002)

HLA-DRB1 amino acid position 13

0.04 (0.02)

HLA-DRB1 amino acid positions 13 and 67

0.04 (0.02)

h2SNP, heritability; HLA, human leucocyte antigen; RF, rheumatoid factor.

position 67, additional association at HLA-DPB1*02:01, an
effect at HLA-A and at HLA-B. There is previous evidence for
association of HLA-DPB1*0201 and HLA-A*02 (we found
stronger association considering amino acids, speciﬁcally a
valine residue at HLA-A amino acid position 95 in HLA-A*02).
Previous studies have failed to demonstrate an association with
HLA-B, which are apparent only with the additional samples
available for this study.
A striking ﬁnding has been the shared association of
HLA-DRB1 amino acid position 13 for both paediatric and
adult diseases. It is known that amino acid position 13 is
involved in shaping the peptide-binding pocket 4 of
HLA-DRB1.16 We ﬁnd that the association in the combined oligoarthritis and RF-negative polyarthritis dataset mirrors the
ﬁndings seen in seronegative RA and similarly, in RF-positive
polyarthritis, the ﬁndings correspond to the association in seropositive RA. Interestingly, the magnitudes of associations are
stronger in the paediatric diseases compared with adult, suggesting the paediatric disease is more genetically driven.
We then further compared the associations seen in each of the
other JIA categories with those of their proposed adult counterparts. Based on clinical features, it is likely that sJIA would map
to adult Still’s disease, but there is currently no HLA genetic
data to support or refute this. The most signiﬁcant association
in sJIA was for HLA-DRB1*11, consistent with recent ﬁndings
from a large genome-wide association study for sJIA, which
used an overlapping set of samples.17 Previous studies of a HLA
association with sJIA had yielded conﬂicting results, but there is
now clear evidence for association of the HLA region with this
category of JIA. Data from the current study also show that the
association is distinct to that seen in the other categories. This
supports emerging evidence that sJIA is a distinct disease, with
less of an autoimmune phenotype and displaying autoinﬂammatory features18 and builds on previous genetic
evidence, which reported no association with another wellestablished JIA susceptibility gene, PTPN22, in sJIA.19
Unsurprisingly, the strongest association seen in ERA,
HLA-B*27, is the same as adult AS.20 Although no associations
reaching genome-wide level of signiﬁcance ( p<5×10−8) were
seen in jPsA, the most signiﬁcant HLA alleles were
HLA-DQA1*0401 ( p=0.0001), HLA-DRB1*08 ( p=0.0003)
and HLA-DQB1*0402 ( p=0.0008), which all lie on the same
haplotype. The established HLA association in adult-onset PsA
is HLA-C*0602,21 which is also the primary HLA association in
psoriasis,22 was also modestly associated in this study
( p=0.008). There was also evidence in jPsA for association with
HLA-B*27 ( p=0.003), the HLA allele that is the most
770

signiﬁcant in ERA. The mixed HLA associations in jPsA may
suggest some misclassiﬁcation such that the jPsA samples may
contain some individuals from oligoarthritis, RF-negative polyarthritis or ERA categories. This is perhaps not surprising given
that jPsA is difﬁcult to classify, and that some of the jPsA classiﬁcation criteria have been disputed.23
The results of this study have important implications for
understanding disease pathogenesis, aetiology and potential
future therapeutic strategies for JIA categories. Despite the development of a classiﬁcation system, heterogeneity still exists within
the ILAR categories. This heterogeneity of JIA remains a key
challenge to paediatric rheumatologists; however, these results
may inform the debate on classiﬁcation and help deﬁne a more
biological-driven and molecular-driven classiﬁcation system. We
show clear differences among many of the categories in terms of
their HLA associations, but here we have also shown that the
most common categories of JIA, oligoarthritis and RF-negative
polyarthritis, are genetically similar and also notably similar to
adult-onset seronegative RA. It is only relatively recently that the
heterogeneous nature of adult RA has been recognised, with seronegative RA less common than seropositive RA.24 25 There are
no speciﬁc therapeutic strategies for seronegative RA at this time,
but given the rarity of this subphenotype of RA and the JIA categories individually, this study suggests that further comparisons
of genetic studies for these diseases could help identify novel
pathways and targets for therapy for both adult-onset and
childhood-onset forms of inﬂammatory arthritis.
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